评估硬皮病患者体内的 miRNA-126 和 VCAM-1 及其与临床特征的关系。

IF 2.3 4区医学 Q2 MEDICINE, GENERAL & INTERNAL

American Journal of the Medical Sciences Pub Date : 2025-03-01 DOI:10.1016/j.amjms.2024.09.007

Afsaneh Enteshari-Moghadam Specialist , Nasrin Fouladi PhD , Shohreh Pordel MD , Farhad Jeddi PhD , Vahid Asghariazar MSc , Majid Eterafi MSc , Elham Safarzadeh PhD

{"title":"评估硬皮病患者体内的 miRNA-126 和 VCAM-1 及其与临床特征的关系。","authors":"Afsaneh Enteshari-Moghadam Specialist , Nasrin Fouladi PhD , Shohreh Pordel MD , Farhad Jeddi PhD , Vahid Asghariazar MSc , Majid Eterafi MSc , Elham Safarzadeh PhD","doi":"10.1016/j.amjms.2024.09.007","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Systemic sclerosis (SSc) has the highest level of mortality and disability among all rheumatological diseases. Being heterogenous leads to no predictable method for clinical courses. The aim of this study was to evaluate the levels of miRNA-126 and soluble VCAM-1 protein markers in patients with SSc, and to examine the assossiation of their levels with the severity of clinical and paraclinical parameters in patients with SSc.</div></div><div><h3>Method</h3><div>In current study tweny six patients with SSc along with twenty-three SSc-free controls were recruited. Enzyme-linked immunosorbent assay (ELISA) was performed to measure the VCAM-1 protein. MiRNA-126 amounts in serum were detected by quantitative real-time polymerase chain reaction (PCR).</div></div><div><h3>Result</h3><div>SSc patients' average age was 45.42 years and control group 49.85. The mean±SD for circulating miR-126 levels were significantly lower in SSc patients compared with healthy donors (<em>p</em> = 0.02), 0.48 ± 0.72 vs 1.11 ± 0.61 respectively. A significant difference was also observed in the serum level of miRNA-126 in SSc patients who suffer from pulmonary artery hypertension (<em>P</em> = 0.03) and pulmonary fibrosis (<em>P</em> = 0.04). In contrast, analysis of the serum VCAM-1 levels in the study groups uncovered a significant increase in SSc patients (5.92 ± 3.52 µg/ml) compared to control group (2.62 ± 1.2 µg/ml) (P value < 0.001).</div></div><div><h3>Conclusion</h3><div>Significant change in circulating levels of miR-126 and VCAM-1 in the SSc patients supporting its role in the pathogenesis of the disease. It could also proposed potential role as a predictor of pulmonary complications for miRNA-126.</div></div>","PeriodicalId":55526,"journal":{"name":"American Journal of the Medical Sciences","volume":"369 3","pages":"Pages 339-345"},"PeriodicalIF":2.3000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the miRNA-126 and VCAM-1 in scleroderma patients and its association with clinical characteristics\",\"authors\":\"Afsaneh Enteshari-Moghadam Specialist , Nasrin Fouladi PhD , Shohreh Pordel MD , Farhad Jeddi PhD , Vahid Asghariazar MSc , Majid Eterafi MSc , Elham Safarzadeh PhD\",\"doi\":\"10.1016/j.amjms.2024.09.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Systemic sclerosis (SSc) has the highest level of mortality and disability among all rheumatological diseases. Being heterogenous leads to no predictable method for clinical courses. The aim of this study was to evaluate the levels of miRNA-126 and soluble VCAM-1 protein markers in patients with SSc, and to examine the assossiation of their levels with the severity of clinical and paraclinical parameters in patients with SSc.</div></div><div><h3>Method</h3><div>In current study tweny six patients with SSc along with twenty-three SSc-free controls were recruited. Enzyme-linked immunosorbent assay (ELISA) was performed to measure the VCAM-1 protein. MiRNA-126 amounts in serum were detected by quantitative real-time polymerase chain reaction (PCR).</div></div><div><h3>Result</h3><div>SSc patients' average age was 45.42 years and control group 49.85. The mean±SD for circulating miR-126 levels were significantly lower in SSc patients compared with healthy donors (<em>p</em> = 0.02), 0.48 ± 0.72 vs 1.11 ± 0.61 respectively. A significant difference was also observed in the serum level of miRNA-126 in SSc patients who suffer from pulmonary artery hypertension (<em>P</em> = 0.03) and pulmonary fibrosis (<em>P</em> = 0.04). In contrast, analysis of the serum VCAM-1 levels in the study groups uncovered a significant increase in SSc patients (5.92 ± 3.52 µg/ml) compared to control group (2.62 ± 1.2 µg/ml) (P value < 0.001).</div></div><div><h3>Conclusion</h3><div>Significant change in circulating levels of miR-126 and VCAM-1 in the SSc patients supporting its role in the pathogenesis of the disease. It could also proposed potential role as a predictor of pulmonary complications for miRNA-126.</div></div>\",\"PeriodicalId\":55526,\"journal\":{\"name\":\"American Journal of the Medical Sciences\",\"volume\":\"369 3\",\"pages\":\"Pages 339-345\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of the Medical Sciences\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0002962924014745\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of the Medical Sciences","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002962924014745","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

摘要

背景：在所有风湿病中，系统性硬化症（SSc）的死亡率和致残率最高。由于具有异质性，临床病程没有可预测的方法。本研究旨在评估系统性硬化症患者体内 miRNA-126 和可溶性 VCAM-1 蛋白标志物的水平，并研究其水平与系统性硬化症患者临床和辅助临床参数严重程度的关系：方法：本研究招募了 206 名 SSc 患者和 23 名无 SSc 的对照组。采用酶联免疫吸附试验（ELISA）检测VCAM-1蛋白。通过定量实时聚合酶链反应（PCR）检测血清中 MiRNA-126 的含量：结果：SSc 患者的平均年龄为 45.42 岁，对照组为 49.85 岁。与健康供体相比，SSc 患者循环 miR-126 水平的平均值（±SD）明显降低（p = 0.02），分别为 0.48 ± 0.72 vs 1.11 ± 0.61。患有肺动脉高压（P = 0.03）和肺纤维化（P = 0.04）的 SSc 患者血清中的 miRNA-126 水平也有明显差异。相反，对研究组血清中 VCAM-1 水平的分析发现，与对照组（2.62 ± 1.2 µg/ml）相比，SSc 患者的 VCAM-1 水平（5.92 ± 3.52 µg/ml）显著增加（P 值 < 0.001）：SSc患者循环中的miR-126和VCAM-1水平发生了显著变化，支持其在疾病发病机制中的作用。这也可能是 miRNA-126 预测肺部并发症的潜在作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Evaluation of the miRNA-126 and VCAM-1 in scleroderma patients and its association with clinical characteristics

Background

Systemic sclerosis (SSc) has the highest level of mortality and disability among all rheumatological diseases. Being heterogenous leads to no predictable method for clinical courses. The aim of this study was to evaluate the levels of miRNA-126 and soluble VCAM-1 protein markers in patients with SSc, and to examine the assossiation of their levels with the severity of clinical and paraclinical parameters in patients with SSc.

Method

In current study tweny six patients with SSc along with twenty-three SSc-free controls were recruited. Enzyme-linked immunosorbent assay (ELISA) was performed to measure the VCAM-1 protein. MiRNA-126 amounts in serum were detected by quantitative real-time polymerase chain reaction (PCR).

Result

SSc patients' average age was 45.42 years and control group 49.85. The mean±SD for circulating miR-126 levels were significantly lower in SSc patients compared with healthy donors (p = 0.02), 0.48 ± 0.72 vs 1.11 ± 0.61 respectively. A significant difference was also observed in the serum level of miRNA-126 in SSc patients who suffer from pulmonary artery hypertension (P = 0.03) and pulmonary fibrosis (P = 0.04). In contrast, analysis of the serum VCAM-1 levels in the study groups uncovered a significant increase in SSc patients (5.92 ± 3.52 µg/ml) compared to control group (2.62 ± 1.2 µg/ml) (P value < 0.001).

Conclusion

Significant change in circulating levels of miR-126 and VCAM-1 in the SSc patients supporting its role in the pathogenesis of the disease. It could also proposed potential role as a predictor of pulmonary complications for miRNA-126.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American Journal of the Medical Sciences 医学-医学：内科

CiteScore

4.40

自引率

0.00%

发文量

303

审稿时长

1.5 months

期刊介绍： The American Journal of The Medical Sciences (AJMS), founded in 1820, is the 2nd oldest medical journal in the United States. The AJMS is the official journal of the Southern Society for Clinical Investigation (SSCI). The SSCI is dedicated to the advancement of medical research and the exchange of knowledge, information and ideas. Its members are committed to mentoring future generations of medical investigators and promoting careers in academic medicine. The AJMS publishes, on a monthly basis, peer-reviewed articles in the field of internal medicine and its subspecialties, which include: Original clinical and basic science investigations Review articles Online Images in the Medical Sciences Special Features Include: Patient-Centered Focused Reviews History of Medicine The Science of Medical Education.